N/A N=732 Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Participants Reporting Adverse Events — 6.56 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=19 A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
Obesity
Primary: Weight Loss — 2.0 percentage of weight
Phase 3 N=19 Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percentage of Participants Who Were Responders After 1 Week of Treatment With Study Medication — 68.4 percentage of participants
Phase 3 N=307 A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
Chemotherapy Induced Nausea and Vomiting
Primary: Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1 — 50.7; 26.0 Percentage of participants — p=<0.01
N/A N=28 A Clinical Investigation Examining the Performance and Handling of New 2-piece Ostomy Products in 28 People With an Ileostomy.
Ileostomy - Stoma
Primary: Degree of Leakage — 6.4; 3.4; 7.0; 7.0 units on a scale
Phase 2 N=221 Maintenance of Platelet Inhibition With Cangrelor
Acute Coronary Syndrome (ACS)
Primary: Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay…
N/A N=53 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
Phase 2 N=30 Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Dose Limiting Toxicity (DLT) — 5 Dose Limiting Toxicities
Phase 2 N=315 Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
Phase 3 N=54 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion — 410.4; 6.7 milliseconds (ms)
N/A N=35 Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece
Hair Removal
Primary: Hair Count — 54 percentage of hair clearance — p=<0.001
Phase 3 N=254 Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
Diphtheria · Polio · Pertussis
Primary: Percentage of Participants With Pre-booster Antibody Persistence and Booster Response to DTaP-IPV-Hep B-PRP~T After Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T…
Phase 4 N=16 Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel
Periodontal Disease
Primary: Pharmacokinetics — 89.9; 41.8; 3.72; 5.13 ng/mL
Phase 3 N=12 Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Pediculosis
Primary: Participants With a Change in Cholinesterase Level at 1 Hour (Day 0). — -1.8; -0.5 percentage change in cholinesterase
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants